Neuronetics' Revenue Surges 132% YoY, Positions as Neurohealth Leader with FDA Clearance for Adolescent TMS Therapy.

Neuronetics, Inc. (NASDAQ:STIM) reported Q2 2025 revenue of $38.1 million, a 132% YoY increase, driven by Greenbrook integration and expansion to 95 clinics. The company is expanding its SPRAVATO program and gained FDA clearance for NeuroStar in adolescents, establishing it as a first-line therapy. Revenue for fiscal 2025 is projected between $149 million and $155 million, with positive cash flow from operations anticipated by Q4 2025. The business continues investing in growth and talent, navigating challenges in profitability and stock volatility.